August 13, 2007 |
Daniel GRAY'S stomach tells a story. The gnarled lines across his abdomen are the mementos of three major surgeries on his digestive system. The slashes along each side are reminders of the time the stitches broke and the doctors put him into a drug-induced coma for seven weeks, keeping his abdomen open for repeated washes. The doctors made the slits so that they would have enough skin to stretch over the opening when they finally sewed him together.
October 28, 2006 |
An international scientific team has pinpointed a gene mutation that appears to protect some people from Crohn's disease. The finding could pave the way for diagnostic tools and drugs to treat Crohn's, a chronic inflammation primarily of the small intestine, which afflicts more than 500,000 people in the U.S. Typically diagnosed before age 30, it causes diarrhea, abdominal pain, bleeding and weight loss. "Once you get it, you pretty much have it for life," said Dr. Steven R.
December 3, 2004 |
Isis Pharmaceuticals Inc. said its experimental drug alicaforsen failed as a treatment for Crohn's disease in two late-stage trials. The Carlsbad, Calif.-based biotechnology company said it would focus on getting alicaforsen approved as an enema for patients with ulcerative colitis, a use shown to be effective in phase-two studies. Isis shares rose $1.09 to $6.01 on Nasdaq.
November 15, 2004 |
An experimental drug that selectively tamps down part of the immune system can offer dramatic relief to many victims of the painful bowel disorder Crohn's disease, and might also work against illnesses such as arthritis and multiple sclerosis, researchers have found. Other drugs are already available against Crohn's, but their effectiveness is spotty. This is the first study to show that a certain immune system protein could be key to the poorly understood disease.
August 25, 2004 |
The Food and Drug Administration and manufacturer Centocor are warning doctors that patients receiving the drug Remicade to treat rheumatoid arthritis and Crohn's disease have suffered sometimes fatal blood and central nervous system disorders. The Malvern, Pa.-based company has revised the drug's label.
January 2, 2003 |
An experimental drug shows promise as an effective new approach for treating multiple sclerosis and the intestinal ailment Crohn's disease. In preliminary tests, the new drug Antegren dramatically reduced the number of new brain lesions in patients with MS and cut the number of relapses in half. In Crohn's patients, it increased the rate of remission and improved the patients' quality of life. There were few serious side effects.